2 completed, 1 available, 1 recruiting. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Lafora Disease: new trials by email Literature Review of Lafora Disease trials Research Report on Lafora Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Safety and Efficacy of Intrathecally Administered ION283 in Patients With Lafora Disease ION283 - Lafora Disease | Phase 1 / Phase 2 | Recruiting | Berge Minassian | 10 | 2024-12-03 | 2025-12-18 |
| Natural History and Functional Status Study of Patients With Lafora Disease Lafora Disease | Completed | Ionis Pharmaceuticals, Inc. | 33 | 2019-01-09 | 2022-09-28 | |
| Ketogenic Diet in Lafora Disease Lafora Disease | Completed | National Institute of Neurological Disorders and Stroke (NINDS) | 15 | 2000-12-01 | 2008-03-04 | |
| Intravenous VAL-1221 Lafora Expanded Access Protocol VAL-1221 - Lafora Disease | Available | Parasail, LLC | 2023-07-05 |
Glycogen Storage Disease (2) · Dementia (1) · Epilepsies, Myoclonic (1) · Epilepsy (1) · Insulin Resistance (1) · Myoclonic Epilepsies, Progressive (1) · Myoclonus (1) · Seizures (1)
Brain Diseases (4) · Central Nervous System Diseases (4) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4) · Epilepsy, Generalized (4) · Epileptic Syndromes (4) · Genetic Diseases, Inborn (4) · Heredodegenerative Disorders, Nervous System (4) · Nervous System Diseases (4) · Neurodegenerative Diseases (4) · Epilepsies, Myoclonic (3) · Epilepsy (3) · Metabolic Diseases (3) · Myoclonic Epilepsies, Progressive (3) · Nutritional and Metabolic Diseases (3) · Carbohydrate Metabolism, Inborn Errors (2)
Berge Minassian (1) · Ionis Pharmaceuticals, Inc. (1) · National Institute of Neurological Disorders and Stroke (NINDS) (1) · Parasail, LLC (1)
United States (3) · Italy (1) · Spain (1)